Ironwood Investment Management LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 36.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,770 shares of the biopharmaceutical company’s stock after selling 20,000 shares during the period. Ironwood Investment Management LLC’s holdings in Pfizer were worth $973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Regal Investment Advisors LLC lifted its position in Pfizer by 7.3% during the second quarter. Regal Investment Advisors LLC now owns 282,398 shares of the biopharmaceutical company’s stock valued at $7,901,000 after purchasing an additional 19,091 shares during the last quarter. Quarry LP bought a new stake in shares of Pfizer in the 2nd quarter worth about $31,000. Wallace Advisory Group LLC purchased a new position in shares of Pfizer during the second quarter valued at approximately $434,000. William B. Walkup & Associates Inc. purchased a new position in Pfizer during the 2nd quarter valued at $1,100,000. Finally, Sunbelt Securities Inc. lifted its position in shares of Pfizer by 9.7% during the second quarter. Sunbelt Securities Inc. now owns 60,258 shares of the biopharmaceutical company’s stock worth $1,686,000 after purchasing an additional 5,350 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.
Pfizer Price Performance
Shares of Pfizer stock opened at $29.09 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The business has a 50 day simple moving average of $29.31 and a two-hundred day simple moving average of $28.30. The stock has a market capitalization of $164.84 billion, a P/E ratio of -484.83, a PEG ratio of 1.27 and a beta of 0.68. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $34.11.
Analyst Ratings Changes
PFE has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, September 16th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Wells Fargo & Company upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. UBS Group lifted their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.
Check Out Our Latest Stock Analysis on PFE
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
- Five stocks we like better than Pfizer
- Are Penny Stocks a Good Fit for Your Portfolio?
- Watch These 3 Former Short-Squeeze Stocks for a Big Rally
- Best Stocks Under $10.00
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- The 3 Best Retail Stocks to Shop for in August
- CarMax’s Impressive Rally: What Investors Should Watch Next
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.